Abstract:Background The development of pathological cardiac hypertrophy involves the coordination of a series of transcription activators and repressors, while their interplay to trigger pathological gene reprogramming remains unclear. NULP1 (nuclear localized protein 1) is a member of the basic helix‐loop‐helix family of transcription factors and its biological functions in pathological cardiac hypertrophy are barely understood. Methods and Results Immunoblot and immunostaining analyses showed that NULP1 expression was consistently reduced in the failing hearts of patients and hypertrophic mouse hearts and rat cardiomyocytes. Nulp1 knockout exacerbates aortic banding‐induced cardiac hypertrophy pathology, which was significantly blunted by transgenic overexpression of Nulp1 . Signal pathway screening revealed the nuclear factor of activated T cells (NFAT) pathway to be dramatically suppressed by NULP1. Coimmunoprecipitation showed that NULP1 directly interacted with the topologically associating domain of NFAT3 via its C‐terminal region, which was sufficient to suppress NFAT3 transcriptional activity. Inactivation of the NFAT pathway by VIVIT peptides in vivo rescued the aggravated pathogenesis of cardiac hypertrophy resulting from Nulp1 deficiency. Conclusions NULP1 is an endogenous suppressor of NFAT3 signaling under hypertrophic stress and thus negatively regulates the pathogenesis of cardiac hypertrophy. Targeting overactivated NFAT by NULP1 may be a novel therapeutic strategy for the treatment of pathological cardiac hypertrophy and heart failure. Nonstandard Abbreviations and Acronyms AB aortic banding Ad adenoviral Ang II angiotensin II CAT chloramphenicol acetyltransferase Col1 Collagen Type I Col3 Collagen Type III Ctgf connective tissue growth factor Gapdh glyceraldehyde‐3‐phosphate dehydrogenase LVEDd left ventricular end‐diastolic diameter MCM MerCreMer Myh7 β‐myosin heavy chain NFAT nuclear factor of activated T cells NRVM neonatal rat ventricular myocyte NULP1 nuclear localized protein 1 PE phenylephrine WGA wheat germ agglutinin α/β‐MHC α/β‐myosin heavy chain Clinical Perspective What Is New? NULP1 (nuclear localized protein 1) expression is consistently decreased in heart samples from patients with heart failure and in heart tissues from mice with aortic banding‐induced cardiac hypertrophy. NULP1 negatively regulates nuclear factor of activated T cells (NFAT) signaling independent of calcineurin via specifically interacts with NFAT3 and suppresses its overactivated transcriptional activity under hypertrophic stress. Inactivation of NFAT by inhibitor VIVIT reversed the exacerbated hypertrophic pathology after Nulp1 deficiency. What Are the Clinical Implications? The development of cardiac hypertrophy involves the coordination of a series of transcription activators and repressors, whereas their interplay to trigger pathological gene reprogramming remains unclear. We identify a transcription repressor, NULP1, acts as a negative regulator of pathological cardiac hypertrophy by suppressing NFAT3 transcriptional activity. Targeting overactivated NFAT by NULP1 may be a novel therapeutic strategy for the treatment of pathological cardiac hypertrophy and hea -Abstract Truncated-

NULP1 Alleviates Cardiac Hypertrophy by Suppressing NFAT3 Transcriptional Activity.

Inhibition of TRPC1 Prevents Cardiac Hypertrophy Via NF-κB Signaling Pathway in Human Pluripotent Stem Cell-Derived Cardiomyocytes.

Nucleoporin 35 Regulates Cardiomyocyte Ph Homeostasis by Controlling Na+-H+ Exchanger-1 Expression.

Hint1 (Histidine Triad Nucleotide-Binding Protein 1) Attenuates Cardiac Hypertrophy Via Suppressing Hoxa5 (Homeobox A5) Expression

TNIP3 protects against pathological cardiac hypertrophy by stabilizing STAT1

Nuclear Receptor Corepressor 1 Represses Cardiac Hypertrophy

CDC-like kinase 4 deficiency contributes to pathological cardiac hypertrophy by modulating NEXN phosphorylation

Nfat Transcription Factors Are Critical Survival Factors That Inhibit Cardiomyocyte Apoptosis During Phenylephrine Stimulation In Vitro

Control of Pathological Cardiac Hypertrophy by Transcriptional Corepressor IRF2BP2 (interferon Regulatory Factor-2 Binding Protein 2).

Signal Transducer and Transcriptional Activation 1 Protects Against Pressure Overload‐induced Cardiac Hypertrophy

Smad Nuclear Interacting Protein 1 Acts as a Protective Regulator of Pressure Overload-Induced Pathological Cardiac Hypertrophy.

Therapeutic Inhibition of LincRNA-p21 Protects Against Cardiac Hypertrophy

Targeting E3 Ubiquitin-Ligase WWP1 Prevents Cardiac Hypertrophy Through Destabilizing DVL2 via Inhibition of K27-Linked Ubiquitination

Leucine zipper protein 1 attenuates pressure overload-induced cardiac hypertrophy through inhibiting Stat3 signaling

Nucleosome assembly protein 1 like 1 (NAP1L1) promotes cardiac fibrosis by inhibiting YAP1 ubiquitination and degradation

Neuregulin-1β Partially Improves Cardiac Function in Volume-Overload Heart Failure Through Regulation of Abnormal Calcium Handling.

Carabin: Endogenous Calcineurin Inhibitor, a Potential Diagnostic and Therapeutic Target for Cardiac Hypertrophy in Heart Failure

3′ untranslated region of Ckip-1 inhibits cardiac hypertrophy independently of its cognate protein

Peroxisome proliferator–activated receptor gamma coactivator 1 alpha protects cardiomyocytes from hypertrophy by suppressing calcineurin-nuclear factor of activated T cells c4 signaling pathway

SENP1 Protects Against Pressure Overload-Induced Cardiac Remodeling and Dysfunction Via Inhibiting STAT3 Signaling

NFATc4 and Myocardin Synergistically Up-Regulate the Expression of LTCC Α1c in ET-1-induced Cardiomyocyte Hypertrophy.